14 completed, 4 active not recruiting, 3 enrolling by invitation, 3 not yet recruiting. 7 Phase 2, 6 Phase 3, 5 Not applicable, 4 Phase 1, 1 Early Phase 1.
Follow Chikungunya Virus Infection: new trials by email Literature Review of Chikungunya Virus Infection trials Research Report on Chikungunya Virus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Against Chikungunya Virus and Neonatal Infection plasma transfusion : PC-CHIK-V - Chikungunya Virus Infection, Neonatal | Not applicable | Recruiting | Centre Hospitalier Universitaire de la Réunion | 60 | 2027-08-01 | 2026-09-15 |
| A Phase I Study of PepGNP-ChikV in Healthy Volunteers PepGNP-ChikV, Placebo - Chikungunya, Chikungunya Fever | Early Phase 1 | Not yet recruiting | Gylden Pharma Ltd | 40 | 2026-08-03 | 2026-04-29 |
| VLA1553-403 Pregnancy Surveillance Study Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH - Chikungunya Virus Infection | Enrolling by invitation | Valneva Austria GmbH | 200 | 2026-06-11 | 2026-07-20 | |
| A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children VLA1553, Control - Chikungunya Virus Infection | Phase 3 | Withdrawn | Valneva Austria GmbH | 2026-02-06 | 2025-12-31 | |
| Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection | Active not recruiting | Valneva Austria GmbH | 5000 | 2026-02-02 | 2026-07-21 | |
| Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection | Enrolling by invitation | Valneva Austria GmbH | 1200 | 2026-02-02 | 2026-07-17 | |
| Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection | Active not recruiting | Valneva Austria GmbH | 5354 | 2025-09-22 | 2026-02-11 | |
| Xpert® Tropical Fever Test on GeneXpert® Edge X System Xpert Tropical Fever test - Malaria Fever, Zika | Enrolling by invitation | Cepheid | 2500 | 2025-08-18 | 2026-04-09 | |
| Chikungunya Virus Detection in Semen semen, blood and urine tests - Chikungunya Virus Infection | Not applicable | Not yet recruiting | University Hospital, Toulouse | 15 | 2025-05-01 | 2025-05-21 |
| Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana IXCHIQ, VIMKUNYA - Chikungunya Virus Infection | Phase 4 | Recruiting | Centre Hospitalier Universitaire de la Réunion | 1505 | 2025-04-18 | 2026-09-28 |
| Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases Peripheral venous blood sample - Leishmaniasis, Leptospirosis | Not applicable | Not yet recruiting | University Hospital, Montpellier | 183 | 2025-03-03 | 2025-03-05 |
| A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) VLA1553 - Chikungunya Virus Infection | Phase 3 | Withdrawn | Valneva Austria GmbH | 2024-04-10 | 2024-12-02 | |
| A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years VLA1553 full dose, VLA1553 half dose, Control - Chikungunya Virus Infection | Phase 2 | Completed | Valneva Austria GmbH | 304 | 2023-12-18 | 2026-08-13 |
| Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination CHIKV VLP vaccine booster, Placebo booster - Chikungunya Virus Infection | Phase 3 | Active not recruiting | Bavarian Nordic | 715 | 2023-08-30 | 2026-08-07 |
| Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) VLA1553 - Chikungunya Virus Infection | Phase 3 | Active not recruiting | Valneva Austria GmbH | 363 | 2021-04-02 | 2026-07-09 |
| Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults Biological Vaccine VLA1553 - Chikungunya Virus Infection | Phase 3 | Completed | Valneva Austria GmbH | 409 | 2021-02-22 | 2023-09-28 |
| Phase 1 Study of SAR440894 vs Placebo Placebo, SAR440894 - Chikungunya Virus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 42 | 2020-10-14 | 2026-01-13 |
| Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults VLA1553, Placebo - Chikungunya Virus Infection | Phase 3 | Completed | Valneva Austria GmbH | 4128 | 2020-09-17 | 2023-06-28 |
| Consequences of a Maternal-fetal Chikungunya Virus Infection OPHTHALMOLOGICAL ASSESSMENT, NEUROPSYCHOLOGICAL ASSESSMENT - Chikungunya Virus Infection | Not applicable | Completed | Centre Hospitalier Universitaire de la Réunion | 42 | 2020-01-13 | 2024-01-05 |
| Yoga for Chronic Chikungunya Wait-list group, Yoga group - Chikungunya Virus Infection | Not applicable | Terminated | Centre Hospitalier Universitaire de la Guadeloupe | 42 | 2019-10-03 | 2020-07-02 |
Showing 20 of 30. Sign in to see all of them.
Chikungunya Fever (30) · Zika Virus Infection (3) · Communicable Diseases (2) · Dengue (2) · Leptospirosis (2) · Brain Diseases (1) · Brucellosis (1) · Encephalitis, Tick-Borne (1) · HIV Infections (1) · Hantavirus Pulmonary Syndrome (1) · Hepatitis E (1) · Leishmaniasis (1) · Lyme Disease (1) · Malaria (1) · Measles (1)
Alphavirus Infections (30) · Arbovirus Infections (30) · Infections (30) · Mosquito-Borne Diseases (30) · RNA Virus Infections (30) · Togaviridae Infections (30) · Vector Borne Diseases (30) · Virus Diseases (30) · Flaviviridae Infections (3) · Flavivirus Infections (3) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Central Nervous System Diseases (2) · Disease Attributes (2) · Gram-Negative Bacterial Infections (2)
Blood Specimen Collection (1) · Dosage Forms (1) · Measles-Mumps-Rubella Vaccine (1) · Neuropsychological Tests (1) · Seeds (1) · Sodium Chloride (1) · Urinalysis (1)
Valneva Austria GmbH (10) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Centre Hospitalier Universitaire de la Réunion (3) · Themis Bioscience GmbH (3) · Bavarian Nordic (2) · Centre Hospitalier Universitaire de la Guadeloupe (2) · Cepheid (1) · Gylden Pharma Ltd (1) · Universidad de Antioquia (1) · University Hospital Center of Martinique (1) · University Hospital, Montpellier (1) · University Hospital, Toulouse (1)
United States (9) · France (5) · Brazil (4) · Dominican Republic (2) · French Guiana (2) · Guadeloupe (2) · Puerto Rico (2) · Reunion (2) · Austria (1) · Colombia (1) · Germany (1) · Haiti (1) · Honduras (1) · Martinique (1) · Mayotte (1)
Andre Cabie, MD (1) · Bruno Hoen, MD (1) · Cameron Simmons, Prof. (1) · Clemente Diaz, MD (1) · Grace Chen, MD (1) · James McCarty, MD (1) · Jean W Pape, MD (1) · Julie E Ledgerwood, D.O. (1) · Julie Ledgerwood, DO (1) · Nicolas Rosario, MD (1)
PMID 25132507, PMID 25739878, PMID 30409443, PMID 32286643, PMID 33836004, PMID 34582377, PMID 34900237, PMID 35709798, PMID 37321235, PMID 37690874, PMID 38032857, PMID 39146946, PMID 39998495, PMID 41652122, PMID 42174470, PMID 42205143
2014 (1), 2015 (1), 2018 (1), 2025 (1)